Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares Issued
Ratios

Centessa Pharmaceuticals (CNTA) Accumulated Depreciation & Amortization: 2022-2025

Historic Accumulated Depreciation & Amortization for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $237,000.

  • Centessa Pharmaceuticals' Accumulated Depreciation & Amortization rose 0.42% to $237,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $910,000, marking a year-over-year decrease of 5.01%. This contributed to the annual value of $942,000 for FY2024, which is 16.30% up from last year.
  • As of Q3 2025, Centessa Pharmaceuticals' Accumulated Depreciation & Amortization stood at $237,000, which was up 4.87% from $226,000 recorded in Q2 2025.
  • Centessa Pharmaceuticals' 5-year Accumulated Depreciation & Amortization high stood at $246,000 for Q4 2023, and its period low was $28,000 during Q1 2022.
  • For the 3-year period, Centessa Pharmaceuticals' Accumulated Depreciation & Amortization averaged around $221,091, with its median value being $236,000 (2024).
  • As far as peak fluctuations go, Centessa Pharmaceuticals' Accumulated Depreciation & Amortization surged by 640.62% in 2023, and later decreased by 9.58% in 2025.
  • Centessa Pharmaceuticals' Accumulated Depreciation & Amortization (Quarterly) stood at $36,000 in 2022, then soared by 583.33% to $246,000 in 2023, then dropped by 6.50% to $230,000 in 2024, then increased by 0.42% to $237,000 in 2025.
  • Its last three reported values are $237,000 in Q3 2025, $226,000 for Q2 2025, and $217,000 during Q1 2025.